

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS 98:89hington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/415,540	10/08/1999	PHILLIP R. HAWKINS	PF-0148-3 CPA	4965
27904 7	7590 04/17/2003	•		
INCYTE CORPORATION (formerly known as Incyte			EXAMINER	
Genomics, Inc.) 3160 PORTER DRIVE		SLOBODYANSKY, ELIZABETH		
PALO ALTO,	CA 94304		ART UNIT	PAPER NUMBER
			1652	32
		•	DATE MAILED: 04/17/2003	7

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action

Application No.	Applicant(s)
09/415,540	HAWKINS ET AL.
Examin r	Art Unit
Elizabeth Slobodyansky	1652

The MAILING DATE of this communication appears on the cover sheet with the correspondence address
THE REPLY FILED FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may <u>only</u> be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.
PERIOD FOR REPLY [check either a) or b)]
a) The period for reply expiresmonths from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP
To 6.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension see have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension see under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if imely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).
1. A Notice of Appeal was filed on <u>06 March 2003</u> . Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. The proposed amendment(s) will not be entered because:
(a) They raise new issues that would require further consideration and/or search (see NOTE below);
(b) ☐ they raise the issue of new matter (see Note below);
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
(d) they present additional claims without canceling a corresponding number of finally rejected claims. NOTE:
3.⊠ Applicant's reply has overcome the following rejection(s): <u>objection and 112, 2nd, of claim 20</u> .
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7. For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.
The status of the claim(s) is (or will be) as follows:
Claim(s) allowed:
Claim(s) objected to:
Claim(s) rejected: <u>18-20</u> .
Claim(s) withdrawn from consideration:
8. ☐ The proposed drawing correction filed on is a) ☐ approved or b) ☐ disapproved by the Examiner.
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)
10. □ Other: E. Sloboolyansky
Elizabeth Slobodyansky Primary Examiner Art Unit: 1652

U.S. Patent and Trademark Office



Continuation of 5. does NOT place the application in condition for allowance because: 112,1st, written description rejection of claims 18-20 is maintained for the reasons of record. Applicants argue that there are "at least 3 naturally occurring human polynucleotides [that] encode an amino acid sequence (g6563256, g5931602, and g4960208) that are 100% identical to the sequence of SEQ ID NO:1 (Remarks, paragraph bridging pages 3 and 4). This is not persuasive because all three sequences became publicly available after the effective filing date of the instant application of 10/31/96. Furthermore, the sequence that is 100% identical to another sequence is the same sequence not a variant thereof.